Thrombolytic therapy and mechanical interventions are frequently used in the treatment of both arterial and venous thrombotic disease. Limitations to these approaches include failure to achieve reperfusion and complications including bleeding and vessel wall damage. Increasing evidence indicates that the use of ultrasound offers potential therapeutic advantages. This review considers two distinct approaches which include the use of high intensity ultrasound to mechanically fragment clots and also the use of low intensity ultrasound to augment enzymatic fibrinolysis. High intensity ultrasound can be delivered via catheter or transcutaneously to disrupt clots in vitro or in animal models into small fragments. Initial clinical studies demonstrate potential clinical value in peripheral and coronary arterial thrombosis and occluded saphenous vein bypass grafts treated with the catheter approach. Studies in vitro indicate that low intensity ultrasound accelerates enzymatic thrombolysis through non-thermal mechanisms involving improvement in drug transport. The effect is larger at low frequencies, which also offer better tissue penetration and less heating. The ability to accelerate thrombolysis has been confirmed in animal models demonstrating markedly increased reperfusion and minimal toxicity. The use of ultrasound to mechanically disrupt occlusive thrombi or to accelerate enzymatic thrombolysis offers a new approach to treating occlusive thrombotic disease.
Introduction
The use of thrombolytic therapy has expanded as clinical trials have documented its value in common thrombotic diseases. This has resulted in a significant reduction in acute myocardial infarction mortality and morbidity, improved outcomes in patients with peripheral arterial disease and the promise of reduced disability following stroke. These clearly documented benefits have also focused attention on the limitations of thrombolytic therapy and stimulated efforts to improve effectiveness, decrease adverse effects and broaden indications. In treating arterial thrombosis, the critical needs are to establish reperfusion as rapidly as possible and also to prevent reocclusion in the presence of a diseased vessel wall and prothrombotic lesion. Thus, in patients with acute myocardial infarction, up to 20% do not achieve reperfusion, and in those who do reperfuse the benefit decreases with longer periods of ischemia, emphasizing the need for rapidly acting therapy. For stroke, the need for very early treatment and the serious consequences of intracranial bleeding limit application. Problems with thrombolytic treatment of peripheral arterial disease include a requirement for proper catheter placement, a longer duration of treatment, and the need for subsequent endovascular procedures or surgical reconstruction in most patients. Its use for venous thromboembolic disease is primarily in Vascular Medicine Unit, Department of Medicine, University of Rochester School of Medicine & Dentistry, Rochester, NY, USA patients with pulmonary embolism with hemodynamic compromise and in selected patients with large proximal deep vein thrombosis. This reflects the high incidence of therapeutic failure and lower benefit-to-risk ratio. 1, 2 Intense efforts to overcome these obstacles and improve therapy have focused on the development of new plasminogen activators, more effective dosing regimens, and the use of adjunctive antiplatelet and anticoagulant therapies.
The use of ultrasound represents a completely different approach to improving thrombolytic therapy. Since its effects are limited to the insonified region, it offers the potential to solve some of these serious problems by both accelerating reperfusion locally and reducing systemic bleeding complications. This brief review will consider the in vitro studies defining the effect of ultrasound on thrombolysis, review proposed mechanisms of action, discuss animal studies and consider the potential for clinical application.
In vitro studies
The use of ultrasound for thrombolysis has evolved using two fundamentally different approaches to either mechanically disrupt the thrombus using high intensities or to accelerate enzymatic fibrinolysis at lower intensities. Several reports have established that clots can be mechanically disrupted into small fragments using a wire vibrating at ultrasonic frequencies without administration of plasminogen activator. [3] [4] [5] [6] The apparatus consists of an ultrasound transducer which is mechanically coupled to a wire of varying length ensheathed in a catheter. When activated, ultrasound energy is transmitted to the tip which vibrates with high force, resulting in rapid mechanical fragmentation of atherosclerotic plaque or thrombus. Heating of the wire occurs routinely and is typically controlled with infusion of saline through the catheter during activation. Siegel et al 7 demonstrated that such a device could disrupt fibrous or calcified plaque in atherosclerotic arteries recovered at autopsy or surgery, and complete atherosclerotic occlusions of up to 5 cm could be rapidly recanalized even if calcification was present. Application to the normal vessel wall had less effect, but thermal damage occurred in approximately one-third and perforation in over 10%. In a similar study, Ernst et al 8 used samples obtained at autopsy to investigate the capacity of high intensity ultrasound delivered via a wire to ablate atherosclerotic plaque and compared its effect to that on a normal arterial wall. At high power, the ultrasound probe disrupted plaque effectively, but also perforated normal vessel wall, although there was some selectivity for plaque at power intensities of less than 68 W cm −2 .
The second approach is different in concept and applies lower intensity ultrasound to accelerate enzymatic fibrinolysis with minimal or no mechanical disruption of the clot. Several reports have demonstrated enhancement of thrombolysis with ultrasound at frequencies of 0.5 MHz and higher. Francis et al 9 investigated the effect of ultrasound on fibrinolysis in vitro using plasma clots exposed to continuous wave 1-MHz ultrasound at intensities of up to 8 W cm −2 in a temperature-controlled watertank. Significant acceleration of fibrinolysis induced by tissue-plasminogen activator (t-PA) was observed at intensities of 1 W/cm 2 and greater. No mechanical fragmentation was observed, and fibrinolysis did not increase in the absence of plasminogen activator. Ultrasound exposure resulted in a marked reduction in the t-PA concentration required to achieve fibrinolysis ( Figure 1 ), and the effect was also observed with urokinase and streptokinase. 10 A small increase in temperature occurred, but was insufficient to explain the marked enhancement of fibrinolysis. Similar results were observed by Lauer et al 11 at 1.75 W cm −2 and 50% duty cycle, and also by Luo et al 12 who observed acceleration of fibrinolysis with urokinase and streptokinase at 1 MHz and intensities of 1-2.2 W cm −2 . Other reports [13] [14] [15] [16] also observed acceleration of enzymatic fibrinolysis at frequencies of 0.5-2.3 MHz and intensities of up to 5 W cm −2 .
Critical issues in developing ultrasound to enhance thrombolysis for therapeutic application are identification of the optimum frequency and intensity, and some reports indicate that enzymatic thrombolysis may be enhanced at lower ultrasound frequencies. Tachibana 20 have investigated the potential of 40-kHz ultrasound and observed significant acceleration of enzymatic fibrinolysis at intensities as low as 0.25 W cm −2 . The extent of fibrinolysis was intensity-dependent and some mechanical disruption of the clot occurred at 40 kHz, reaching a maximum of 3.8% at 1.5 W cm −2 . The effects on fibrinolysis were strikingly greater than those observed previously at 1 MHz ( Figure 2 ). Tissue attenuation and heating were examined using samples of porcine rib cage, and was only 1.7 Ϯ 0.5 dB through the intercostal space and 3.4 Ϯ 0.9 dB through rib. Temperature increments in rib were less than 1°C W −1 cm −2 .
The capacity to enhance fibrinolysis at lower frequencies is critical for several reasons. First, at high frequencies, the attenuation of soft tissues will reduce the intensity of the field with external application to a degree that adequate treatment may be provided only for clots in peripheral ves-sels and unacceptable heating may occur. The attenuation of bone is, however, at least an order of magnitude greater than soft tissue, and the use of high frequency ultrasound for non-invasive treatment of heart or brain is, therefore, essentially precluded. In contrast, the depth of penetration of 40 kHz or lower in soft tissues is, for practical purposes, infinite, and the rib cage transmits approximately one-half of the incident intensity to the heart. Wavelengths of several centimeters at these frequencies also mean that beam patterns are broad and relatively uniform even after passing through the chest wall. Also, there is a rather large intensity window between the minimum values that are effective in enhancing thrombolysis and the levels that would be thermally hazardous. At mid-kHz frequencies, even the brain may be accessible for non-invasive treatment with ultrasound. A review of published data 20 on attenuation of skull bone indicates that even at 300 kHz, the intensity transmitted should be greater than one-third of the incident level and that attenuation is roughly proportional to the frequency, suggesting that at 40 kHz the ultrasound intensity reaching the brain with thermally acceptable levels should be great enough to enhance enzymatic thrombolysis. This has recently been confirmed by Akiyama et al 21 who found that 40% of ultrasound intensity could be transmitted through temporal bone and also by Behrens et al 22 who observed only 0.1 dB transtemporal attenuation by 33 kHz with human skull.
Most studies examining enhanced enzymatic fibrinolysis have focused on the potential use of externally applied ultrasound, but miniaturized transducers have also been attached to catheters for endovascular use, and this offers the potential to deliver localized ultrasound at the site of thrombosis while limiting the insonification of normal tissue. Tachibana 18 demonstrated enhanced clot lysis in vitro using a transducer operating at 225 kHz attached to a catheter with a wire connecting it to an external power source. Enhancement of thrombolysis in vitro was also found using a 170-kHz transducer at 0.5 W cm −2 , 23 and Shlansky-Goldberg et al 24 observed acceleration of whole blood clot lysis using a 640-kHz catheter-mounted transducer with urokinase. The results with catheter-mounted transducers are qualitatively similar to those with larger transducers for external application and offer the prospect of insonifying a much smaller area but require endovascular manipulation.
Evidence from these in vitro studies is compelling that low intensity ultrasound can accelerate enzymatic thrombolysis using clots of purified fibrin, plasma or whole blood with all thrombolytic agents tested including urokinase, streptokinase and t-PA. The effect is large and appears to be intensity-dependent, with acceleration of up to sevenfold in comparison with no ultrasound at 40 kHz. Ultrasound can also be used in the form of a wire placed in direct contact with clots and activated at high power to mechanically fragment it.
Mechanisms
The mechanisms by which ultrasound accelerates thrombolysis appear to be multiple and complex. Wires vibrating at ultrasonic frequencies and high intensities cause mechanical disruption through direct contact with the clot, but indirect effects through cavitation may also play a role. In a study of the mechanism of ultrasound angioplasty, Rosenschein et al 25 examined the effect of 20-kHz ultrasound at intensities up to 100 W cm −2 . The cavitation threshold with this system was over 30 W, and ultrasound ablation was only evident above the cavitation threshold, and its rate correlated directly with increasing ultrasound power. In hydroxyproline gelatin samples, the zone of ablation could be viewed with a telemicroscopy device, and this confirmed the role of cavitation in mechanical disruption of the gel.
The mechanisms by which ultrasound enhances enzymatic thrombolysis appear primarily related to enzyme transport into the clot, a rate limiting step in therapeutic thrombolysis. 26 Francis et al 27 examined the effect of insonification on the distribution of radiolabeled plasminogen activator between the clot and surrounding fluid in vitro to determine if accelerated thrombolysis induced by ultrasound could be related to increased transport of enzyme into the clot. In the presence of 1-MHz ultrasound at 4 W cm −2 , the uptake of activator was significantly faster in the presence of ultrasound, and crytome sectioning demonstrated that activator was transported deeper into the clot. These results demonstrated that exposure to ultrasound in the absence of fluid permeation increases both total uptake and depth of penetration, effects that would accelerate clot dissolution. Enzyme transport may also occur through fluid permeation, and Siddiqi et al 28 examined the effect of ultrasound on pressure-mediated flow through fibrin gels. Exposure to 1-MHz ultrasound at 2 W cm −2 resulted in a significant increase in flow through the gel which was intensity-dependent and reversible when ultrasound was discontinued.
Flow through gels at constant pressure is determined by resistance, a property of fibrin structure. Therefore, Braaten et al 29 examined the effect of ultrasound on the ultrastructure of fibrin gels using scanning electron microscopy. Gels exposed to ultrasound exhibited an increase in the number of fibrin fibers per unit volume accompanied by a concomitant decrease in mean fiber diameter ( Figure 3 ). The effects were reversible, and there was no significant change in the structure of fibrin after ultrasound was discontinued. These results indicate that ultrasound exposure caused a reversible disaggregation of fibrin fibers, an effect that would alter flow resistance and create additional binding sites for plasminogen activators, thereby improving fibrinolytic efficiency. The binding of plasminogen activator and plasminogen to fibrin is important in determining the rate of fibrinolysis. Because ultrasound altered fibrin structure, Siddiqi et al 30 characterized the effects of ultrasound on binding of t-PA to fibrin. Whereas ultrasound had little effect on the binding affinity of t-PA, maximum binding was significantly increased; ultrasound also affected the kinetics, significantly accelerating the rate of interaction of t-PA with fibrin. The findings indicate that ultrasound exposure may accelerate fibrinolysis by altering the interactions of t-PA with fibrin, increasing both maximum binding and also access of t-PA to fibrin binding sites.
Thrombolysis in animal models
The favorable results obtained in vitro have led to studies in animal models with separate approaches examining either mechanical disruption or enhancement of enzymatic fibrinolysis. Several studies examined the capacity of high intensity ultrasound delivered via catheter to disrupt arterial or venous thrombi without administration of plasminogen activator. In an early study, Trubestein et al 31 formed venous or arterial thrombi in dog iliac or femoral vessels. These were then exposed to 26.5-kHz ultrasound at high intensity delivered through a catheter wave guide, and the disrupted clot was aspirated through a suction device. Clots were ablated within 5 min, and flow was rapidly re-established with only minor endothelial cell damage observed histologically. Similar results were obtained by Rosenschein et al 4 using a 20-kHz ultrasound wire at a power of 20 Ϯ 10 W to ablate femoral artery thrombi in dogs, findings that were confirmed by the work of Ariani et al. 5 In a canine coronary thrombosis model, Steffen et al 6 achieved recanalization in 13 or 15 occluded coronary arteries in an average of 7 min using a 19.5-kHz ultrasound catheter. Although no vessel perforation or dissection occurred, histologic exam revealed focal mural thrombus remaining, and there was histologic evidence of vessel wall injury including transmural necrosis with hemorrhage in some cases.
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Successful results have also been reported using low intensity ultrasound to accelerate enzymatic thrombolysis. Hamano 32 reported that the combination of t-PA and 20-kHz ultrasound delivered transcutaneously in a canine femoral artery thrombosis model reduced the time to reflow from 58 Ϯ 32 min with urokinase alone to 20 Ϯ 20 min with the combination of urokinase and ultrasound. Riggs et al 33 used a rabbit femoral artery thrombosis model with streptokinase in the presence or absence of ultrasound at 1 MHz and 2 W cm −2 applied over the thrombosed segment. Thrombolysis occurred in 53% of animals receiving ultrasound compared to 17% without (p = 0.025), with a maximum temperature increase of 4°C. Different results were obtained by Kornowski et al, 34 who used a rabbit femoral artery thrombosis model and treatment with t-PA alone or in combination with externally applied ultrasound at 1 MHz and 6.3 W cm −2 . The transducer was positioned 10-15 cm above the arterial clots. Although initial reflow occurred faster with ultrasound, there was also greater reocclusion, so that arterial patency was lower overall with ultrasound than in its absence. A beneficial effect of aspirin in combination with ultrasound suggested that the higher rate of reocclusion with ultrasound was due to platelet activation, which had been observed in earlier in vitro studies. 35 Luo et al 36 used 26-kHz ultrasound at 18 W cm −2 in a rabbit femoral artery thrombosis model and demonstrated increased reperfusion with ultrasound plus streptokinase compared with either ultrasound or streptokinase alone. Using a different approach, Kashyap et al 37 demonstrated acceleration of fibrinolysis with 1-MHz transcutaneous ultrasound at 1 W cm −2 in a rabbit model of small vessel thrombolysis.
Recently, Suchkova et al 38 have demonstrated that 40-kHz ultrasound at a low intensity of 0.75 W cm −2 resulted in significant enhancement of streptokinse-induced fibrinolysis in a rabbit femoral artery thrombosis model. Ultrasound was delivered transcutaneously and there was minimal heating or evidence of vascular injury histologically. Additionally, ultrasound reversed ischemia of nonperfused muscle even in the absence of thrombolysis as reflected by normalization of tissue pH and capillary perfusion. This effect was reversible, and suggested that ultrasound may both accelerate fibrinolysis and improve tissue perfusion by improving collateral flow in ischemic tissue.
Evidence also indicates that newly available stabilized microbubble echocontrast agents may be used to further augment the cavitation-dependent effects of ultrasound on thrombolysis. Nishioka et al 39 were able to reperfuse thrombosed rabbit femoral arteries with transcutaneous administration of 20-kHz ultrasound at 1.5 W cm −2 in combination with the echocontrast agent, dodecafluoropentane, without administration of plasminogen activator. Ultrasound delivery, however, resulted in skin necrosis and severe histologic changes due to heating, but this could be minimized by using a cooling device. 40 Also, Birnbaum et al 41 evaluated 37 kHz ultrasound in combination with PESDA microbubbles and no plasminogen activation, demonstrating recanalization of 10/10 thrombosed rabbit ileofemoral arteries. The potential of microbubble echocontrast agents to enhance the effect of ultrasound in vivo is consistent with similar findings in vitro. 23, 42 Siegel et al 43 examined the effect of low frequency ultrasound on coronary thrombolysis in a canine model. Thrombotic occlusion of the left anterior descending coronary artery was induced and two groups of dogs were treated with either t-PA alone or in combination with 27-kHz ultrasound at 0.9 W cm −2 delivered percutaneously through the chest to the artery. At 90 min there was significantly greater coronary flow in dogs receiving the combination of t-PA plus ultrasound than in those treated with t-PA alone.
Another recent study emphasizing the switch to lower intensity ultrasound was reported by Suchkova et al 38 using a rabbit femoral artery thrombosis model. Treatment was administered with either ultrasound alone at 40 kHz and 0.75 W cm −2 , streptokinase alone, or the combination of both ultrasound and streptokinase. Ultrasound or streptokinase alone resulted in minimal thrombolysis, but reperfusion was nearly complete with the combination after 120 min. The maximum temperature increase after 60 min of treatment was 1.6 Ϯ 1.3°C at the femoral artery and 1.1 Ϯ 0.7°C at the femur. A novel finding in these experiments was that ultrasound improved tissue perfusion independent of its effect on thrombolysis. In the absence of femoral artery flow, application of ultrasound caused capillary dilation, improved capillary perfusion as measured with a Vascular Medicine 2001; 6: 181-187 laser-Doppler flowmeter, and also reversed muscle acidosis. These effects were reversible and declined after ultrasound was removed. Histologic examination showed that an ultrasound-exposed vessel had a tendency toward endothelial cell vacuolization, with some cells lifted from the basement membrane.
In general, the results of animal experiments are consistent with those in vitro, and demonstrate the potential of ultrasound to accelerate lysis of both arterial or venous thrombi. In the absence of plasminogen activator, high intensity ultrasound delivered through an endovascular catheter directly to the thrombus can result in mechanical ablation and recanalization. Heating of the wire, vessel wall damage and perforation are complications, and the effects of distal embolization of clot fragments must be considered. The non-invasive transcutaneous delivery of lower intensity ultrasound in combination with a plasminogen activator can accelerate thrombolysis with minimal evidence of vessel wall damage and acceptable heating. Vasodilation of capillaries in the ischemic area may also be of benefit. At higher ultrasound intensities external application can result in significant thermal damage of both skin and deep tissue injury.
Clinical trials
Catheter-delivered high intensity ultrasound has been used to mechanically recanalize vessels in small clinical studies. Siegel et al 44 used an ultrasound wire at 20 kHz and a power output of 20-35 W cm −2 in a 7 F catheter to treat eight patients with peripheral arterial disease. Recanalization occurred within 2 min in three of four patients with complete occlusions and reduced the degree of stenosis in others. In a subsequent study, 45 percutaneous ultrasound angioplasty was performed on 50 arterial lesions in 45 patients using a probe operating at 19.5 kHz. Recanalization occurred in 30 of 35 totally occluded arteries, and stenosis was reduced in 13 of 15 patients. Arterial dissection occurred in four patients and arterial perforation in an additional four, but these were without serious clinical consequence. Ultrasound angioplasty has also been used to recanalize occluded peripheral arteries in seven patients using a 20-kHz ultrasound wire operating between 5 and 35 W. 46 Successful recanalization was documented angiographically in over 80% of patients. Recanalization in seven of nine patients with severe leg ischemia using an ultrasound wire operating at 42 kHz was also reported by Goyen et al. 47 Ultrasound has also been used in small studies to explore treatment of coronary artery thrombosis. In a feasibility study, Siegel et al 48 reported success with a 19.5-kHz ultrasound ablation device operating between 16 W and 20 W in pulsed mode. Ultrasonic coronary angioplasty was also performed during coronary artery bypass grafting in 20 patients. 49 Successful recanalization occurred in 70% of attempts, but arterial perforation complicated the procedure in 10% of vessels. Analysis of the plaque debris showed that 95% of particles resulting from the procedure were less than 25 m in diameter. A study of 15 consecutive patients with acute anterior myocardial infarction used a flexible ultrasound wire activated at 45 kHz and 18 W to induce reperfusion in 87% with no obvious complications. 50 Similar results were reported by Hamm et al 51 using a 19.5-kHz wire in 14 patients. Rosenschein et al 52 have recently reported successful recanalization of occluded saphaneous vein bypass grafts using an ultrasound device with a 1.6mm tip within a 7 F guiding catheter operated at 41 kHz and 18 W. Successful recanalization was observed in 70% of patients, and complications included a single non-Twave myocardial infarction and distal embolization in one additional patient.
Summary
The application of ultrasound may be a useful adjunct in the treatment of thrombotically occluded vessels. High intensity ultrasound delivered through a catheter can recanalize a thrombosed vessel segment through a direct mechanical or cavitational effect. Problems with this approach include the need for specialized angiographic facilities, catheter heating and malfunction, and also potential injury to the vessel wall. Low intensity ultrasound can be used to enhance enzymatic fibrinolysis, accelerating clot dissolution up to sevenfold in vitro, using transducers for either percutaneous or endovascular administration. At frequencies in the range of 40 kHz, tissue penetration is excellent and significant acceleration of fibrinolysis is possible at intensities causing minimal heating. The particular advantages of ultrasound to accelerate thrombolysis include its locally limited effect, minimal apparent adverse effects and the potential to use lower doses of plasminogen activator, thereby reducing systemic bleeding complications. Initial, small, clinical studies demonstrate the ability of endovascular application of an ultrasound wire to recanalize occluded peripheral and coronary arteries.
